Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


ChemGenics Pharmaceuticals

Division of Takeda Pharmaceutical Co. Ltd.

Latest From ChemGenics Pharmaceuticals

Millennium's Vision Thing

Millennium's purchase of Leukosite appears to be a significant step towards its oft-stated goal of building a fully integrated pharmaceutical company. But some of the company's investors reacted less enthusiastically as stock prices tumbled immediately after the deal. Since then, the company's share price has almost returned to pre-deal levels. And Millennium's management says that it will reap tremendous benefits as the result of acquiring Leukosite's pipeline and late-stage clinical development capabilities,

The New Structures of Platform Deals

Platform deals are still occurring, but thanks to the changing economics of the pharmaceutical industry, particularly drug companies' infatuation with late-stage deals, platform deal structures are changing. Dollar values are generally lower; tech transfer is more common; royalties and product-based milestones rarer.
BioPharmaceutical Strategy

Structuring for Strength

Barry Berkowitz is developing a new business model: a biopharmaceutical holding company called Strong Pharmaceuticals Inc. will provide management support to three separate platform companies.
BioPharmaceutical Strategy

Biotech Models, Part II: Early-Stage Companies

The goal is financing through dealmaking, not repeated trips to the equity markets. The problem is how to create a strategy for doing plenty of deals without surrendering the upside.
BioPharmaceutical Strategy
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Takeda Pharmaceutical Co. Ltd.
  • Senior Management
  • Barry A Berkowitz, PhD, Pres. & CEO
    Robert Morgan, CFO
    Alan L Crane, Exec. Dir., Bus. Dev.
    William Timberlake, PhD, EVP, Research
  • Contact Info
  • ChemGenics Pharmaceuticals
    Phone: (617) 374-9090
    One Kendall Square
    Building 300
    Cambridge, MA 02139